We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


New Data Show Rubicon’s Amplification Technology Enables Genetic and Epigenetic Analyses of Single Cells Using Next-Gen Sequencing

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "New Data Show Rubicon’s Amplification Technology Enables Genetic and Epigenetic Analyses of Single Cells Using Next-Gen Sequencing"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
Rubicon Genomics reported data demonstrating that its PicoPlex™ kits currently marketed for the analysis of single cells for research and diagnostic applications also provide important advantages for genetic and epigenetic profiling using next-generation sequencing (NGS).

The new PicoPlex-NGS WGA (whole genome amplification) and PicoPlex-NGS WMA (whole methylome amplification) kits are designed to produce sensitive and reproducible genomic and epigenomic data for cancer, stem cell and embryology applications.

Data on Rubicon's new kits were highlighted during the initial lecture at the Single Cell Analysis Summit (SCAS) in San Diego last week and will also be presented at the 2010 American Society of Human Genetics (AHSG) Annual Meeting being held November 2-6, 2010 in Washington DC.

PicoPlex is Rubicon’s proprietary method of extracting and amplifying total DNA from single cells and other precious samples-producing relatively large amounts of DNA for genetic and epigenetic profiling analyses in just 3-5 hours. PicoPlex delivers the highest linearity and reproducibility and the lowest background of any commercially-available amplification technology, enabling a wide range of microarray and PCR applications where accuracy and reproducibility are important.

“Our PicoPlex kits have been widely adopted for PCR and microarray testing for pre-implantation genetic screening and diagnostics for in vitro fertilization procedures, where high accuracy and speed are essential,” noted Dr. John Langmore, Vice President of Commercial Development at Rubicon. “Building on that success, we have adapted the PicoPlex technology for the analysis of single cells in the demanding fields of cancer and stem cell research and therapy.”

Dr. Langmore added, “The unique attributes of our amplification technologies will enable many types of genetic analyses that previously were not possible, and we look forward to working with our growing international customer base to bring the benefits of PicoPlex-NGS to a wide variety of research and clinical applications. We currently are making beta versions of our new kits available to researchers conducting next-generation sequencing studies using cancer cells. stem cells and environmental samples, and we invite interested researchers to visit us at ASHG or contact the company.”

At the 2010 ASHG meeting, Rubicon is presenting NGS data from small tissue samples prepared using its new whole methylome amplification technology for preparation of DNA libraries for epigenetic research. Next-generation DNA sequencing has revolutionized epigenetic research by enabling the profiling of differentially-methylated DNA regions associated with cancer and other diseases. However, current protocols for preparing the libraries needed for these analyses require days of complex and laborious preparation.

Rubicon’s MethylPlex-NGS WMA is a automatable process for preparation of libraries for genome-wide methylation profiling. It is substantially simpler, sensitive and faster than existing methods, requiring only 20-50 nanograms of input DNA and 4.5 hours of total preparation time. MethylPlex WMA also deletes non-relevant sequences and ensures enrichment of the highly methylated DNA fragments.